Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection

Handbook of Experimental Pharmacology

Volumn 189, Issue , 2009, Pages 321-346

  Zeuzem, Stefan ^a   Hofmann, Wolf Peter ^b   Soriano, Vincent ^b  

^a GOETHE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; A 831; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ACH 806; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMANTADINE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BOCEPREVIR; CILUPREVIR; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; DEBIO 25; DIDANOSINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; GS 9132; ITMN 191; LAMIVUDINE; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; ZIDOVUDINE; INTERFERON;

ADD ON THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DYSLIPIDEMIA; FATIGUE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; KNOWLEDGE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; ANIMAL; DRUG COMBINATION; DRUG EFFECT; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERONS;

EID: 61549094730     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-79086-0_12     Document Type: Review

References (92)

1. Afdhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, McEniry D, Zhou XJ, Chao G, Fang C, Fielman B, Myers M, Brown N (2004) Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 40 Suppl 1:726
2. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T, Miyake S (2005) Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43(4):623-629
3. Barreiro P, Soriano V, Casas E, Gonzalez-Lahoz J (2002) Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. Aids 16(2):245-249
4. Barreiro P, Jimenez-Nacher I, Garcia B, Garcia-Benayas T, Rivas P, Soriano V (2005) Nucleoside/nucleotide backbones for the treatment of HIV infection. Curr Opin Investig Drugs 6(8):812-822
5. Barreiro P, del Romero J, Leal M, Hernando V, Asencio R, de Mendoza C, Labarga P,Nunez M, Ramos JT, Gonzalez-Lahoz J, Soriano V (2006) Natural pregnancies in HIVserodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 43(3):324-326
6. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37(3):600-609
7. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130(4):1086-1097
8. Bichko V, Qu l, La Colla M, Tausek M, Bergelson S, Pierra C, Storer R, Gosselin G, Sommadossi JP, Standring D (2005) Characterization of NM283 (Valopicitabine) resistance profile using bovine viral diarrhea. Hepatology 42(1):534A
9. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107(3):812-817
10. Carr A, Emery S, Law M, Puls R, Lundgren JD, PowderlyWG (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361(9359):726-735
11. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK, Hung LC, Lee YT, Tam JS, Lam CW, Sung JJ (2005) A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142(4):240-250
12. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, deHertogh D, Wilber R, Colonno R, Apelian D (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354(10):1001-1010
13. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65-73
14. Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350(10):1023-1035
15. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wohrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E (2007) Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369(9568):1169-1178
16. Colonno R, Rose R, Pokornowski K, Yu C (2007) Four year assessment of ETV resistance in nucleoside-näive and lamivudine refractory patients. J Hepatol 46 Suppl 1:S294
17. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ (2006) Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44(6):1656-1665
18. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H (2004) Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40(6):1260-1265
19. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J (2003) Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38(3):645-652
20. de Mendoza C, Soriano V (2004) Resistance to HIV protease inhibitors: Mechanisms and clinical consequences. Curr Drug Metab 5(4):321-328
21. de Mendoza C, Rodriguez C, Colomina J, Tuset C, Garcia F, Eiros JM, Corral A, Leiva P, Aguero J, Torre-Cisneros J, Pedreira J, Viciana I, del Romero J, Saez A, Ortiz de Lejarazu R, Soriano V (2005a) Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 41(9):1350-1354
22. de Mendoza C, Rodriguez C, Eiros JM, Colomina J, Garcia F, Leiva P, Torre-Cisneros J, Aguero J, Pedreira J, Viciana I, Corral A, del Romero J, Ortiz de Lejarazu R, Soriano V (2005b) Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis 41(2):227-232
23. de Mendoza C, Valer L, Ribera E, Barreiro P, Martin-Carbonero L, Ramirez G, Soriano V (2006) Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. HIV Clin Trials 7(4):163-171
24. de Mendoza C, Morello J, Garcia-Gasco P, Rodriguez-Novoa S, Soriano V (2007) Tipranavir: A new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. Expert Opin Pharmacother 8(6):839-850
25. Di Bisceglie AM, Shindo M, Fong TL, FriedMW, SwainMG, Bergasa NV, Axiotis CA,Waggoner JG, Park Y, Hoofnagle JH (1992) A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16(3):649-654
26. Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F (2004) Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 140(1):72-73
27. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman ZD, Crowther L, Condreay L, Woessner M, Rubin M, Brown NA, for the USLIG (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263
28. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl JMed 355(22):2283-2296
29. Embrey MW,Wai JS, Funk TW, Homnick CF, Perlow DS, Young SD, Vacca JP, Hazuda DJ, Felock PJ, Stillmock KA, Witmer MV, Moyer G, Schleif WA, Gabryelski LJ, Jin L, Chen I, Ellis JD, Wong BK, Lin JH, Leonard YM, Tsou NN, Zhuang L (2005) A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6] naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg Med Chem Lett 15:4550-4554
30. Fattovich G, Stroffolini T, Zagni I, Donato F (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5) Suppl 1:S35-S50
31. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975-982
32. Fung SK, Lok AS (2004) Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 40(4):790-792
33. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS (2006) Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44(2):283-290
34. Garcia-Gasco P, Blanco F, Soriano V (2005) Integrase inhibitors. J HIV Ther 10(4):75-78
35. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C (2000) Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32(4 Pt 1):847-851
36. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348(9):800-807
37. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer HC Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM (2004) Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355
38. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA (2006) Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Top HIV Med 14(3):827-843Havlir DV, Richman DD (1996) Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 124(11):984-994
39. Hinrichsen H, Benhamou Y,Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Cronlein J, Chaves RL, Yong CL, Nehmiz G, Steinmann GG (2004) Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127(5):1347-1355
40. Hofmann WP, Polta A, Herrmann E, Mihm U, Kronenberger B, Sonntag T, Lohmann V, Schonberger B, Zeuzem S, Sarrazin C (2007) Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 132(3):921-930
41. Hoofnagle JH, Seeff LB (2006) Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355(23):2444-2451
42. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454):123-129
43. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD (2006) Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14(3):125-130
44. Kieffer T, Sarrazin C,Miller J, Traver S, Zhou Y, Bartels D, Hanzelka B, Muh U, Lin C, Reesink H, Kwong A, Zeuzem S (2006) Combination of telaprevir (VX-950) and PEG-IFN-alfa suppresses both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14-day phase 1b study. Hepatology 44(4):222A-223A
45. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF (1998) A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339(2):61-68
46. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA (2005) A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129(2):528-536
47. Lai CL, Gane E, Hsu CW, Thongsawat S, Wang YM, Chen YG, Heathcote EJ, Rasenack J, Bzowej N, Naoumov N, Zeuzem S, Di Bisceglie A, Chao GC, Constance BAF, Brown NA (2006a) Two-year results from the globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. Hepatology 44(4):222A-222A
48. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, deHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L (2006b) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354(10):1011-1020
49. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M (2005) Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42(6):1414-1419
50. Lau DTY, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH (2000) Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32(4 Pt 1):828-834
51. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352(26):2682-2695
52. Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11(2):97-107
53. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG,Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33(6):1527-1532
54. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119(1):172-180
55. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15):1521-1531
56. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R (2005) High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41(2):275-279
57. Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45(2):507-539
58. Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ (2003) Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 98(10):2261-2267
59. Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, Caronia S, Foster GR, Zeuzem S, Berg T, Di MV, Cino N, Andriulli A (2004) Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol 40(3):478-483
60. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352(25):2609-2617
61. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958-965
62. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348(9):808-816
63. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351(12):1206-1217
64. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339(21):1485-1492
65. Mihm U, Herrmann E, Sarrazin C, Zeuzem S (2006) Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 23(8):1043-1054
66. Pawlotsky JM (2005) Current and future concepts in hepatitis C therapy. Semin Liver Dis 25(1):72-83
67. Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, Gonzalez-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V (2004) Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 74(1):21-28
68. Poveda E, Briz V, Quinones-Mateu M, Soriano V (2006). HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. Aids 20(10):1359-1367
69. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352(9138):1426-1432
70. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Chu HM, Jansen PLM (2005) Final results of a phase 1b multiple dose study of VX950, a hepatitis C virus protease inhibitor. Hepatology 42(1):234AReiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, Riba N, Yong CL, Nehmiz G, Steinmann GG (2005) Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41(4):832-835
71. Rodriguez-Novoa S, Barreiro P, Jimenez-Nacher I, Soriano V (2006) Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J 6(4):234-245
72. Sarin SK, Sood A, KumarM, Arora A, Amrapurkar D, Sharma BC, Konar A, Chawla YK, Jain RK, Nanda V, Kumar A, Hissar S, Lavate P, Lahoti D (2007) Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 102(1):96-104
73. Sarrazin C, Kieffer T, Bartels D, Hanzelka B, MÅ h U, Welker M, Wincheringer D, Lin C, Grossmann T, Purdy S, Weegink C, Reesink H, Zeuzem S, Kwong A (2005) Characterization of viral variants in the HCV NS3 protease domain of genotype 1 patients that are selected during 14 days of dosing with VX-950. Hepatology 42(1):751A
74. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S (2007) SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132(4):1270-1278
75. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, Loria A, Poupon R (2001) Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 34(3):573-577
76. Shiffman M, Pappas S, Nyberg L, Greenbloom S, Gibas A, Bacon B, Rasenack J, Suter F, Diago M, Lin A, Soman A, Zeuzem S (2007) Peginterferon alfa-2a plus ribavirin for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. N Engl J Med 357(2):124-134
77. Sidwell RW, Huffman JH, Khare GP, Allen LB,Witkowski JT, Robins RK (1972) Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4- triazole-3-carboxamide. Science 177(50):705-706
78. Sung JJY, Lai JY, Zeuzem S, Chow WC, Heathcote E, Perrillo R, Brosgart C, Woessner M, Scott SA, Campbell FM (2003) A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): Week 52 analysis. J Hepatol 38:25-26
79. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF (1999) Efficacy of lamivudine in patients with hepatitis B e antigennegative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29(3):889-896
80. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA (2006) Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70(2):28-38
81. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Haussinger D, Herrmann E, Zeuzem S (2005) Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129(2):522-527
82. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166(15):1632-1641
83. Wohnsland A, Hofmann WP, Sarrazin C (2007) Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 20(1):23-38
84. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL (2007) A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56(4):553-559
85. Yuen MF, Lai CL (2006) Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology 49(1-2):96-98
86. Yuen MF, Lai CL (2007) Combination therapy for chronic hepatitis B: Simultaneous or sequential? Am J Gastroenterol 102(1):105-106
87. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343(23):1666-1672
88. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40(6):993-999
89. Zeuzem S, Pawlotsky JM, Lukasiewicz E, vonWagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU (2005a) International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 43(2):250-257
90. Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Brion N, Forestier N, Gupta S, Deckman D, Fellows K, Hussain M, Cutler DL, Zhang J (2005b) Anti-viral activity of SCH503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFNalfa). Hepatology 42(1):233A
91. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44(1):97-103
92. Zoulim F (2006) Antiviral therapy of chronic hepatitis B. Antiviral Res 71(2-3):206-215